公开(公告)号：US20190209513A1

公开(公告)日：2019-07-11

申请号：US16330900

申请日：2017-09-07

申请人： AKAMARA THERAPEUTICS, INC.

发明人： Shiladitya SENGUPTA ,  Aniruddha SENGUPTA ,  Sanghamitra MYLAVARAPU ,  Monideepa ROY

IPC分类号： A61K31/282 ,  C07F15/00 ,  A61K31/575 ,  A61K9/00 ,  C07H23/00 ,  A61P35/04 ,  C07J41/00

CPC分类号： A61K31/282 ,  A61K9/0019 ,  A61K31/575 ,  A61K33/24 ,  A61P35/04 ,  C07F15/0006 ,  C07H23/00 ,  C07J41/00 ,  C07J41/0055 ,  C07J51/00

摘要： The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity in a mammal, using a compound of Formula I and/or Formula II, preferably Compound 1 or its derivative, salt, tautomeric form, isomer, polymorph, solvate, or intermediates thereof. The method of inducing an immune response in a mammal is mediated through immune memory. The present invention also provides for such platinum based compounds and their use in treating cancer, metastasis or cancer relapse.

公开(公告)号：US20240342128A1

公开(公告)日：2024-10-17

申请号：US18751933

申请日：2024-06-24

申请人： AKAMARA THERAPEUTICS, INC.

发明人： Shiladitya SENGUPTA ,  Aniruddha SENGUPTA ,  Sanghamitra MYLAVARAPU ,  Monideepa ROY

IPC分类号： A61K31/282 ,  A61K9/00 ,  A61K31/575 ,  A61K33/243 ,  A61P35/04 ,  C07F15/00 ,  C07H23/00 ,  C07J41/00 ,  C07J51/00

CPC分类号： A61K31/282 ,  A61K9/0019 ,  A61K31/575 ,  A61K33/243 ,  A61P35/04 ,  C07F15/0006 ,  C07H23/00 ,  C07J41/00 ,  C07J41/0055 ,  C07J51/00

摘要： The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity in a mammal, using a compound of Formula I and/or Formula II, preferably Compound 1 or its derivative, salt, tautomeric form, isomer, polymorph, solvate, or intermediates thereof. The method of inducing an immune response in a mammal is mediated through immune memory. The present invention also provides for such platinum based compounds and their use in treating cancer, metastasis or cancer relapse.

公开(公告)号：US20190002489A1

公开(公告)日：2019-01-03

申请号：US16123430

申请日：2018-09-06

申请人： Akamara Therapeutics, Inc.

发明人： Shiladitya SENGUPTA ,  Monideepa Roy ,  Arindam Sarkar ,  Sk Samad Hossain ,  Aniruddha Sengupta ,  Pradip Kumar Dutta ,  Aasif Ansari

IPC分类号： C07F15/00 ,  C07J41/00 ,  C07H23/00

摘要： The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to platinum based compounds comprising platinum moiety, linker moiety and lipid moiety and corresponding nanoparticles thereof. The disclosure further relates to synthesis of said platinum based compounds, nanoparticles and compositions comprising said platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by employing aforesaid carbene compounds, platinum based compounds, nanoparticles and compositions thereof.

公开(公告)号：US20190231894A1

公开(公告)日：2019-08-01

申请号：US16311484

申请日：2017-07-05

申请人： AKAMARA THERAPEUTICS, INC.

发明人： Shiladitya SENGUPTA ,  Sudip ROY ,  Prithvi Raj PANEY

IPC分类号： A61K47/68 ,  A61P35/00 ,  G16B15/30 ,  A61K31/337

CPC分类号： A61K47/6803 ,  A61K31/337 ,  A61K47/60 ,  A61P35/00 ,  G16B15/00 ,  G16B15/20 ,  G16B15/30 ,  G16B40/00 ,  G16C10/00 ,  G16C20/50

摘要： The disclosure provides a process of designing and optimizing supramolecular therapeutics. The disclosure also provides a method for designing and optimizing antibody drug conjugates.

公开(公告)号：US20220168261A1

公开(公告)日：2022-06-02

申请号：US17430849

申请日：2020-02-14

申请人： AKAMARA THERAPEUTICS, INC.

发明人： Heena AGGARWAL ,  Shweta CHAUBEY ,  Rajat DESIKAN ,  Nimish GUPTA ,  Sonia JAIN ,  Seema MITTAL ,  Shiladitya SENGUPTA

IPC分类号： A61K31/282 ,  A61P35/00

摘要： The present disclosure relates to methods of managing cancer by modulating/inhibiting cap methyltransferase enzyme. The modulation/inhibition is carried out by pharmacological or biological inhibitors, including but not limited to compounds of formula (VIII) or Compound A or A-1. Thus, the present disclosure relates to such inhibitors including compounds of formula (VIII) and their use for management of cancer. In some aspects, the compound of formula (VIII) is Compound 1. The present disclosure also relates to methods of activating B cells or T cells via modulation of cap methyltransferases. The present disclosure also relates to methods of managing cancer with a molecule or biologic that generates unmethylated RNA. The generation of unmethylated RNA activates B cells and presents the RNA to B-cell receptor (BCR). The present disclosure therefore also relates to management of cancer by activating B cells and then adoptively transferring the B cells to exert an anticancer effect.